Tcl1 Transgenic Mice
Mouse model for immune system malignancies in B, T and granulocytes cells. Mouse model for B-cell selection, development, maturation, antibody production and signaling responses through PI3-kinase pathways. Mouse model for designing therapeutics against B-cell malignancies and preventing autoantibody production in autoimmune diseases.
UCLA researchers have developed a murine model in which a TCL1 transgene is overexpressed in both B and T cells. These transgenic mice develop Burkitt-like lymphoma and diffuse large B cell lymphoma at 4 months. This phenotype is accompanied by attendant Bcl-6 expression and mutated JH antibody gene segments. Interestingly, TCL1 is a more powerful initiator of B cell malignancies when compared to the low frequency of T cell malignancies with this model. This is mirrored in humans as >85% of human immune system malignancies are B cell derived.
Other Information To complete a Ready-to-Sign Agreement for this case, please view this document. [PDF] Background TCL1 is a protooncogene overexpressed in many mature B cell lymphomas. TCL1 is also expressed in precursor T cells and absent by the CD4+ CD8+ stage of thymocyte development. In B cells, TCL1 is first expressed in pro-B cells, and is completely absent in memory B cells and plasma cells. Related Materials Tech ID/UC Case 20525/2002-274-0 Related Cases 2002-274-0
USA
